China’s Ministry of Commerce said it will lift the export ban on Illumina instruments starting Nov. 10 while keeping the company on an 'unreliable entities' list that requires government approval for purchases; the same action cleared PacBio’s Sequel II CNDx test. Illumina confirmed the announcement and said it would work with Chinese authorities on next steps. The policy reversal restores commercial access to key sequencing platforms in a crucial genomics market and could ease supply chain and sales barriers for sequencing vendors. PacBio’s regulatory clearance for a clinical‑grade HiFi assay signals continued market interest in long‑read platforms for complex clinical sequencing. Companies and clinical labs will now navigate the approvals process, watch procurement workflows, and reassess near‑term sales forecasts for China, a market that had constrained instrument placements since March.